Mostrar el registro sencillo

dc.contributor.authorCamacho Sáez, Blanca
dc.contributor.authorMartínez Taboada, Víctor Manuel 
dc.contributor.authorMerino Fernández, Ana Isabel 
dc.contributor.authorComíns Boo, Alejandra
dc.contributor.authorGonzález-Mesones, Belén
dc.contributor.authorBarrio-Longarela, Sara del
dc.contributor.authorRiancho-Zarrabeitia, Leyre
dc.contributor.authorLópez Hoyos, Marcos 
dc.contributor.authorHernández Hernández, José Luis 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-10-22T14:45:02Z
dc.date.available2024-10-22T14:45:02Z
dc.date.issued2024
dc.identifier.issn2227-9059
dc.identifier.urihttps://hdl.handle.net/10902/34319
dc.description.abstractInherited thrombophilia (IT) has been implicated as a potential causal factor of adverse pregnancy outcomes (APOs), including recurrent miscarriage with and without the presence of antiphospholipid syndrome (APS). The aim of this study was to assess the prevalence and impact of IT on fetal-maternal outcomes and thrombotic risk in women within the spectrum of obstetric APS. Three hundred and twenty-eight women with APS-related obstetric morbidity ever pregnant were included. Of these, 74 met the APS classification criteria, 169 were non-criteria (NC)-APS, and 85 were seronegative (SN)-APS. Patients with other autoimmune diseases were excluded. APOs included early pregnancy loss, fetal death, preeclampsia, abruptio placentae, and preterm birth. Successful pregnancy was defined as the achievement of a live newborn. A literature search was also performed. The mean age of the overall group was 33.9 ± 5.3 years, and the patients were followed up for 35 (11-79) months. During the study period, there were 1332 pregnancies. Nearly 14% of the patients had an associated IT. IT patients more frequently received the standard-of-care (SoC) therapy. The presence of IT was not associated with worse maternal-fetal outcomes in patients treated with SoC treatment. Overall, IT patients had a lower frequency of newborns without treatment, especially those without definite APS. In addition, IT did not increase the risk of thrombosis during pregnancy or the postpartum period. A detailed analysis of the literature review identified only four publications related to our study and did not show conclusive evidence of the impact of IT on patients with obstetric APS. The group of women with APS-related obstetric morbidity and IT who did not receive treatment, especially those without definite APS, had a worse prognosis in terms of a live birth. However, with SoC therapy, the prognosis is similar in those patients without IT. The association of IT with APS does not seem to predispose to the development of thrombosis during pregnancy and/or the postpartum periodes_ES
dc.description.sponsorshipFunding: This research received no external funding.es_ES
dc.format.extent13 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.rights© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines, 2024, 12, 1174es_ES
dc.subject.otherInherited thrombophiliaes_ES
dc.subject.otherPregnancyes_ES
dc.subject.otherObstetric morbidityes_ES
dc.subject.otherFetal losses_ES
dc.subject.otherAntiphospholipid syndromees_ES
dc.subject.otherAntiphospholipid antibodieses_ES
dc.titleImpact of inherited thrombophilia in women with obstetric antiphospholipid syndrome: a single-center study and literature reviewes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/biomedicines12061174
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.